Financially, we continued to diversify our resources through the monetization of the Beleodaq® royalties for $7.5 million. We also set up a line of equity financing, thereby providing the resources to finance our development plan until the next value drivers expected in 2019.
On the sound foundations of these scientific and operational advances, we approach 2019 with serenity. The year will be marked by several key milestones such as conducting the European study of AsiDNA™ in combination and obtaining its first results as well as filing of an Investigational New Drug (IND) application during the second half of the year to initiate clinical trials in the United States.
We are also in the process of finalizing and optimizing our next innovative drug candidate. It originates from our proprietary PlatON™ platform, however its properties differ from those of AsiDNA™. This program is expected to move into regulatory preclinical testing in the coming weeks, thereby strengthening the company's portfolio by capitalizing on our oligonucleotide expertise.
On behalf of the entire team, I thank you for your support and confidence in our strategy to make Onxeo a leading player in oncology. I wish you happiness and success for 2019.
Judith Greciet